Form 4: Pontifax Sells Keros Therapeutics Stake, Directors Resign

Pontifax Management and affiliated funds, along with directors Tomer Kariv and Ran Nussbaum, have sold their entire beneficial ownership in Keros Therapeutics, Inc. for approximately $84.9 million, coinciding with the directors' resignations.

Summary

• Pontifax Management 4 G.P. (2015) Ltd. and its affiliated funds (Pontifax (Israel) IV, L.P., Pontifax (Cayman) IV, L.P., Pontifax (China) IV, L.P., and Pontifax Late Stage Fund, L.P.) have reported the sale of 4,787,331 shares of Keros Therapeutics, Inc. common stock.
• The shares were sold at a price of $17.75 per share on October 15, 2025.
• The total value of the shares sold by these entities amounts to approximately $84,970,000.
• Following these transactions, the Pontifax entities no longer beneficially own any shares in Keros Therapeutics, Inc.
• The sales were made in connection with a Stock Purchase Agreement dated October 15, 2025.
• Directors Tomer Kariv and Ran Nussbaum resigned from Keros Therapeutics' board of directors.
• In connection with their resignations, the vesting of restricted stock unit awards and certain options held by Messrs. Kariv and Nussbaum was accelerated by the Issuer.
• After the reported transactions, Tomer Kariv and Ran Nussbaum each indirectly beneficially own 5,250 shares of Keros Therapeutics, Inc.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the complete divestment by a significant institutional investor (Pontifax) and the simultaneous resignation of two directors who were also 10% owners. This suggests a potential loss of confidence or a strategic exit, which typically weighs on investor sentiment.

Positives

• The acceleration of vesting for restricted stock unit awards and options for resigning directors Tomer Kariv and Ran Nussbaum provides them with immediate liquidity for their equity holdings.

Negatives

• Pontifax Management and its affiliated funds, significant 10% owners, have divested their entire beneficial ownership in Keros Therapeutics, Inc.
• The sale of 4,787,331 shares at $17.75 per share represents a substantial insider selling event.
• Two directors, Tomer Kariv and Ran Nussbaum, who were also 10% owners, have resigned from the board of directors.
• The complete divestment by a major institutional investor and the simultaneous departure of its representatives from the board could signal a loss of confidence or a strategic shift away from the company.

Risks

• The complete divestment by a significant institutional investor (Pontifax) and the resignation of its representatives from the board could be perceived negatively by the market, potentially leading to a decline in investor confidence and share price.
• The departure of experienced directors may impact corporate governance and strategic direction.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance regarding Keros Therapeutics, Inc.'s future performance or strategic direction. However, the complete divestment by a major institutional investor and the resignation of its representatives from the board could imply a change in future strategic alignment or investor support.

Management Comments

• No direct quotes from company management are provided in this Form 4 filing. However, the filing notes that Tomer Kariv, as Chief Executive Officer of Pontifax Management 4 G.P. (2015) Ltd., signed on behalf of several Pontifax entities, and also signed individually.

Industry Context

This Form 4 filing primarily details an insider transaction and board resignations, which are specific to Keros Therapeutics, Inc. and its relationship with Pontifax. It does not provide broader industry trends or competitive analysis. However, in the biotechnology sector, significant insider selling and the departure of major institutional investors and their board representatives can be closely watched by the market as potential indicators of future company performance or strategic shifts.

Comparison to Industry Standards

• This filing reports a significant insider selling event and board resignations, which are not typically compared to specific industry benchmarks or competitor results in a direct financial sense. However, in the context of corporate governance and investor relations, such a large divestment by a 10% owner and the simultaneous departure of directors would generally be viewed as a negative signal compared to industry norms where stable institutional ownership and board continuity are often preferred. No specific comparable companies, projects, or results are mentioned in the filing.

Management Changes

Corporate Governance

Legal Proceedings

• No new legal proceedings or regulatory matters are mentioned in this filing.

Related Party Transactions

• The sale of shares by Pontifax entities, which are 10% owners and have representatives on the board, constitutes a related party transaction.
• The Stock Purchase Agreement dated October 15, 2025, between certain reporting persons and the Issuer, is a related party transaction.
• The Strategic Alliance Agreement dated August 9, 2018, between Pontifax Late Stage Fund, L.P. and the Pontifax IV Funds, is mentioned as a basis for shared voting and dispositive power.

Stakeholder Impact

• Shareholders: May react negatively to the significant insider selling and director resignations, potentially leading to a decrease in share price and investor confidence.
• Employees: No direct impact mentioned, but significant changes in major investors and board composition can sometimes lead to uncertainty.
• Customers/Suppliers/Creditors: No direct impact mentioned in this filing.

Next Steps

• The resignations of Tomer Kariv and Ran Nussbaum from the board of directors are effective.
• The accelerated vesting of restricted stock unit awards and options for Messrs. Kariv and Nussbaum has been completed.
• Keros Therapeutics, Inc. will need to address the vacancies on its board of directors.

Key Dates

Recommendation

The complete divestment by a significant institutional investor (Pontifax) and the simultaneous resignation of two directors who were also 10% owners signals a strong negative sentiment from key insiders. Such a large-scale exit, especially when tied to a 'Stock Purchase Agreement' and board resignations, suggests a strategic decision to reduce exposure to Keros Therapeutics. This action typically indicates a lack of confidence in the company's future prospects from those with deep insight, making it prudent for investors to consider selling their holdings.

Keywords

Keros Therapeutics, KROS, SEC Form 4, Insider Selling, Pontifax, Director Resignation, Stock Sale, Beneficial Ownership, Equity Divestment, Biotechnology